Navigation Links
Newer Blood Pressure Drug No Better Than Placebo in Preventing Stroke
Date:8/27/2008

Patients may need to be on telmisartan longer to see positive effect, researchers say

WEDNESDAY, Aug. 27 (HealthDay News) -- The blood pressure drug telmisartan does not lower the rate of stroke, cardiovascular events or diabetes better than a placebo in patients who have had a stroke, a new study finds.

Telmisartan is an angiotensin II receptor blocker, which works by blocking the action of chemicals that constrict the blood vessels enabling the blood to flow more smoothly, thus lowering blood pressure.

"Overall, there was no difference in the two groups, people taking telmisartan and those taking placebo," said study co-researcher Dr. Ralph L. Sacco, chairman of neurology at the University of Miami's Miller School of Medicine. "However, we did find a difference in that those who were in the study longer the drug had an effect compared to those who were in the study for a short time."

Sacco thinks that the longer someone takes telmisartan may increase its effectiveness in preventing additional strokes. "These effects have not been seen early after a stroke, they may be more delayed," he said. "The follow-up time in this study was only two a half years, and it may have hurt us."

Blood pressure control is essential in preventing strokes, Sacco said. "But this study in itself doesn't say you have to use angiotensin II receptor blocker early," he said. "Other studies have suggested that these drugs may be better for stroke risk reduction, but in this study, we can't say that."

The report was released early in the Aug. 27 issue of the New England Journal of Medicine.

For the study, Sacco's group randomly assigned 20,332 stroke patients to daily doses of telmisartan or placebo. The researchers looked for incidents of stroke in cardiovascular events such as heart attack and heart failure. They also looked for new cases of diabetes.

Over two-and-a-half years of follow-up, 8.7 percent of patients receiving telmisartan suffered a stroke, compared with 9.2 percent of the patients receiving placebo. In addition, 13.5 percent of patients taking telmisartan had a major cardiovascular event versus 14.4 percent of patients in the placebo group. Diabetes occurred in 1.7 percent of patients taking telmisartan and in 2.1 percent of patients receiving placebo.

In a second study in the same issue of the journal, researchers led by Sacco compared the effectiveness of two drug regimens designed to reduce clotting, Persantine (Dipyridamole) plus aspirin or Plavix (clopidogrel) in preventing new strokes among the same group of patients as in the first study.

"The two drugs were essentially the same in terms of their ability to reduce the risk of recurrent stroke, as well as reducing the risk of heart attack and death after a stroke," Sacco said.

During two-and-a-half years of follow-up, 9 percent of the patients taking Persantine and aspirin suffered a stroke compared with 8.8 percent of those taking Plavix. In both groups, 13.1 percent of the patients had a heart attack or died.

"Both drugs are equally effective; neither drug is superior to the other in terms of reducing a recurrent stroke," Sacco said.

Deciding which drug regimen to use depends on the individual patient, Sacco said. "In some patients, we may use Plavix, particularly in those who have cardiac disease, and in some patients, we may still use this combination of Persantine and aspirin. Choices are helpful, since different people respond differently to different medicines," he said.

More information

For more on stroke, visit the American Stroke Association.



SOURCES: Ralph L. Sacco, M.D., chairman, neurology, Miller School of Medicine, University of Miami; Aug. 27, 2008, New England Journal of Medicine online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer antidepressants led to less, not more, teen suicides
2. Newer Antibiotic Speeds TB Healing
3. Newer radiation treatment easier for some throat cancer patients
4. Newer Anticlotting Drug Safe, Effective for Heart Surgeries
5. Newer Sedative Might Help Patients on Ventilators
6. Newer Rheumatoid Arthritis Drugs Lower Production of B Cells
7. Newer Prostate Cancer Treatment Similar to Traditional Surgery
8. Specific antagonism lowers blood pressure
9. Restricting Blood Flow May Help Heart Bypass Patients
10. FDA Updates Prescription Guidelines for Blood Thinner
11. Doctors Often Miss High Blood Pressure in Kids
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Blood Pressure Drug No Better Than Placebo in Preventing Stroke
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... The new ... the individual looking to buy neoprene knee sleeves for lifting and any ... design focuses heavily on two main aspects to provide a higher quality knee sleeve ...
(Date:12/5/2016)... Wallingford, CT (PRWEB) , ... December 05, 2016 ... ... hemostatic devices, announces today that they have teamed up with The American College ... Working with the ACS’s Committee on Trauma, the “Bleeding Control Basic” course is ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... transitions and many more tools allowing FCPX editors to create professional looking video ... Studios. , Perfect Harmony contains a beautifully designed 3D environment for placing ...
(Date:12/4/2016)... Viejo, California (PRWEB) , ... December 04, 2016 ... ... lower third presets that have new attractive animation styles with unique displacement design ... Displace features 30 pre-animated lower third designs. Choose from a variety of design ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with ... preventative dental services to more than 15,900 children 5 years old and younger and ... $38 million over a span of five years to Western University of Health Sciences, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec 5, 2016 Research ... Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease ... - Global Forecasts to 2021" report to their offering. ... , , ... USD 730.7 Million in 2021 from USD 574.8 Million in 2016, ...
(Date:12/5/2016)...   BIOTRONIK today announced the first patients ... the safety and feasibility of performing the minimally invasive ... BioMonitor 2 is an insertable cardiac remote monitor ... a patient,s skin to help physicians accurately detect and ... a leading cause of stroke and heart failure. BioMonitor ...
(Date:12/5/2016)... Dec. 5, 2016  CVS Health, the nation,s largest ... a perfect score of 100 percent on the Corporate ... CEI is an annual national benchmarking survey and report ... administered by the Human Rights Campaign Foundation. ... that our colleagues, customers and suppliers bring to CVS ...
Breaking Medicine Technology: